Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain

Bibliography

• Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg 2007;105:205-21
   PubMed Web of Science ®Google Scholar
• Woolf CJ. Overcoming obstacles to developing new analgesics. Nat Med 2010;16:1241-7
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-81
   PubMed Web of Science ®Google Scholar
• Mao J. Current challenges in translational pain research. Trends Pharmacol Sci 2012;33:568-73
   PubMed Web of Science ®Google Scholar
• Kalliomäki J, Jonzon B, Huizar K, et al. Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy. Scand J Pain 2013;4:77-83
   Google Scholar
• Goldstein DJ, Wang O, Gitter BD, et al. Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol 2001;24:16-22
   PubMed Web of Science ®Google Scholar
• Huggins JP, Smart TS, Langman S, et al. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012;153:1837-46
   PubMed Web of Science ®Google Scholar
• Rice AS, Dworkin RH, McCarthy TD, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2014;383:1637-47
   PubMed Web of Science ®Google Scholar
• Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40-51
   PubMed Web of Science ®Google Scholar
• Tigerstedt R, Bergman PQ. Niere und Kreislauf1. Skand Arch Physiol 1898;8:223-71
   Google Scholar
• Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006;86:747-803
   PubMed Web of Science ®Google Scholar
• Chakrabarty A, Blacklock A, Svojanovsky S, et al. Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. Endocrinology 2008;149:3452-60
   PubMed Web of Science ®Google Scholar
• Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs 2012;21:501-13
   PubMed Web of Science ®Google Scholar
• Muralidharan A, Wyse BD, Smith MT. Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain. Pain Med 2014;15:93-110
   PubMed Web of Science ®Google Scholar
• Patil J, Schwab A, Nussberger J, et al. Intraneuronal angiotensinergic system in rat and human dorsal root ganglia. Regul Peptides 2010;162:90-8
   PubMedGoogle Scholar
• Smith MT, Woodruff TM, Wyse BD, et al. A small molecule angiotensin II Type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen activated protein kinase (MAPK) and p42/p44 MAPK activation in the dorsal root ganglia. Pain Med 2013;14:1557-68
   PubMed Web of Science ®Google Scholar
• Anand U, Facer P, Yiangou Y, et al. Angiotensin II type 2 receptor (AT2 R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 2013;17:1012-26
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Unger T. Angiotensin II type 2 receptor agonists–where should they be applied? Expert Opin Investig Drugs 2012;21:763-6
   PubMed Web of Science ®Google Scholar
• Guimond MO, Roberge C, Gallo-Payet N. Fyn is involved in angiotensin II type 2 receptor-induced neurite outgrowth, but not in p42/p44mapk in NG108-15 cells. Mol Cell Neurosci 2010;45:201-12
   Google Scholar
• Laflamme L, Gasparo M, Gallo JM, et al. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J Biol Chem 1996;271:22729-35
   PubMed Web of Science ®Google Scholar
• Gendron L, Laflamme L, Rivard N, et al. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999;13:1615-26
   Google Scholar
• Stroth U, Blume A, Mielke K, et al. Angiotensin AT(2) receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Brain Res Mol Brain Res 2000;78:175-80
   Google Scholar
• Lucius R, Gallinat S, Rosenstiel P, et al. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998;188:661-70
   PubMed Web of Science ®Google Scholar
• Cote F, Do TH, Laflamme L, et al. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999;274:31686-92
   PubMed Web of Science ®Google Scholar
• Kang J, Sumners C, Posner P. Modulation of net outward current in cultured neurons by angiotensin II: involvement of AT1 and AT2 receptors. Brain Res 1992;580:317-24
   Google Scholar
• Reinecke K, Lucius R, Reinecke A, et al. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 2003;17:2094-6
   PubMedGoogle Scholar
• Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell 2009;139:267-84
   PubMed Web of Science ®Google Scholar
• Smith MT, Wyse BD, Edwards SR. Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding and efficacy in rats. Pain Med 2013;14:692-705
   PubMed Web of Science ®Google Scholar
• Plouffe B, Guimond MO, Beaudry H, et al. Role of tyrosine kinase receptors in angiotensin II AT2 receptor signaling: involvement in neurite outgrowth and in p42/p44mapk activation in NG108-15 cells. Endocrinology 2006;147:4646-54
   PubMed Web of Science ®Google Scholar
• Zhang JM, Strong JA. Recent evidence for activity-dependent initiation of sympathetic sprouting and neuropathic pain. Sheng Li Xue Bao 2008;60:617-27
   Google Scholar
• Devor M. Ectopic discharge in Abeta afferents as a source of neuropathic pain. Exp Brain Res 2009;196:115-28
   PubMed Web of Science ®Google Scholar
• Gold MS, Flake NM. Inflammation-mediated hyperexcitability of sensory neurons. Neurosignals 2005;14:147-57
   Google Scholar
• Zheng Q, Fang D, Cai J, et al. Enhanced excitability of small dorsal root ganglion neurons in rats with bone cancer pain. Mol Pain 2012;8:24
   PubMed Web of Science ®Google Scholar
• Smith MT, Lau T, Wallace VC, et al. Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy. Behav Pharmacol 2014;25:137-46
   Google Scholar
• Smith MT. Method of treatment or prophylaxis of inflammatory pain. US20140142116 A1; 2014
   Google Scholar
• Chakrabarty A, Liao Z, Smith PG. Angiotensin II receptor type 2 activation is required for cutaneous sensory hyperinnervation and hypersensitivity in a rat hind paw model of inflammatory pain. J Pain 2013;14:1053-65
   PubMed Web of Science ®Google Scholar
• Muralidharan A, Wyse BD, Smith MT. Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacol Biochem Behav 2013;106:33-46
   Google Scholar
• Muralidharan A, Smith MT. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology 2013;21:339-63
   Google Scholar
• Black JA, Nikolajsen L, Kroner K, et al. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol 2008;64:644-53
   PubMed Web of Science ®Google Scholar
• Raffa RB, Buschmann H, Christoph T, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother 2012;13:1437-49
   PubMed Web of Science ®Google Scholar
• Smith MT, Moore BJ. Pregabalin for the treatment of fibromyalgia. Expert Opin Pharmacother 2012;13:1527-33
   PubMed Web of Science ®Google Scholar
• Ji RR, Samad TA, Jin SX, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002;36:57-68
   PubMed Web of Science ®Google Scholar
• Hudmon A, Choi JS, Tyrrell L, et al. Phosphorylation of sodium channel Na(v)1.8 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons. J Neurosci 2008;28:3190-201
   PubMed Web of Science ®Google Scholar
• Persson AK, Gasser A, Black JA, et al. Nav1.7 accumulates and co-localizes with phosphorylated ERK1/2 within transected axons in early experimental neuromas. Exp Neurol 2011;230:273-9
   Google Scholar
• Stamboulian S, Choi JS, Ahn HS, et al. ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. J Neurosci 2010;30:1637-47
   Google Scholar
• Martin SW, Butcher AJ, Berrow NS, et al. Phosphorylation sites on calcium channel alpha1 and beta subunits regulate ERK-dependent modulation of neuronal N-type calcium channels. Cell Calcium 2006;39:275-92
   Google Scholar
• Haroutounian S, Nikolajsen L, Bendtsen TF, et al. Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy. Pain 2014;155:1272-9
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for ngf antagonists? Drugs 2014;74:619-26
   PubMed Web of Science ®Google Scholar